Search
H3B-6527
go.drugbank.com/drugs/DB15169InvestigationalH3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).
Micronomicin
go.drugbank.com/drugs/DB13274ApprovedMicronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid
go.drugbank.com/drugs/DB02485ExperimentalA nucleoside monophosphate sugar which donates N-acetylneuraminic acid to the terminal sugar of a ganglioside or glycoprotein. [PubChem]
Clinafloxacin
go.drugbank.com/drugs/DB14025ExperimentalIt has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Exbivirumab
go.drugbank.com/drugs/DB17747ExperimentalIt is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]
Choline C 11
go.drugbank.com/drugs/DB09277ApprovedCholine C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.
Geneticin
go.drugbank.com/drugs/DB04263ExperimentalResistance to Geneticin is conferred by the neo gene from Tn5 encoding an aminoglycoside 3‘-phosphotransferase, APH 3‘ II. … Geneticin blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells and is commonly used in laboratory research to select genetically engineered cells.
α-Methylacetylfentanyl
go.drugbank.com/drugs/DB01532ExperimentalIllicitIt was categorized under the Schedule I in the US and it was illegally sold in early 1980. α-Methylacetylfentanyl synthesis process is very similar to α-methylfentanyl with the substitution of the acetic … anhydride for the production of chemical propionic anhydride in the synthesis.
Tecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
go.drugbank.com/drugs/DB16431Experimentalto the hepatitis B surface antigen[A226593]. … Regarding this vaccine specifically, it stimulates the immune system to produce anti-receptor binding domain antibodies[A226593].